Phenoxymethylpenicillin inhibits the final cross-linking stage of peptidoglycan production through binding and inactivation of transpeptidases on the inner surface of the bacterial cell membrane, thus inhibiting bacterial cell wall synthesis. It may be less active against some susceptible organisms, particularly gm-ve bacteria. It is suitable for mild to moderate infections.
(in Tablet form)
Streptococcal infections of the upper respiratory tract, including scarlet fever and erysipelas:
Adult: 125-250 mg 6-8 hrly for 10 days.
Fusospirochetosis (Vincent’s infection) of the oropharynx, Staphylococcal infections of the skin and soft tissue:
Adult: 250-500 mg 6-8 hrly.
Pneumococcal infections of the respiratory tract, including otitis media:
Adult: 250-500 mg 6 hrly until the patient is afebrile for at least 2 days.
Prophylaxis of recurrent rheumatic fever:
Adult: 250 mg bid.
Adult: 250-500 mg 6 hrly.
Manufacturer: Square Pharmaceutical Ltd.